Doxifluridine

>36.9 [ug/mL] (The mean of the results at pH 7.4)

150.41 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]；145.68 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]；158.54 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]；155.55 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

This chemical does not meet GHS hazard criteria for 16.7% (1 of 6) of reports.

Danger

H226 (16.7%): Flammable liquid and vapor [Warning Flammable liquids]；H315 (33.3%): Causes skin irritation [Warning Skin corrosion/irritation]；H317 (33.3%): May cause an allergic skin reaction [Warning Sensitization, Skin]；H319 (33.3%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]；H332 (16.7%): Harmful if inhaled [Warning Acute toxicity, inhalation]；H335 (16.7%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]；H340 (16.7%): May cause genetic defects [Danger Germ cell mutagenicity]；H350 (16.7%): May cause cancer [Danger Carcinogenicity]；H351 (16.7%): Suspected of causing cancer [Warning Carcinogenicity]；H360 (33.3%): May damage fertility or the unborn child [Danger Reproductive toxicity]；H411 (16.7%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]

P203, P210, P233, P240, P241, P242, P243, P261, P264, P264+P265, P271, P272, P273, P280, P302+P352, P303+P361+P353, P304+P340, P305+P351+P338, P317, P318, P319, P321, P332+P317, P333+P317, P337+P317, P362+P364, P370+P378, P391, P403+P233, P403+P235, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 6 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Reported as not meeting GHS hazard criteria per 1 of 6 reports by companies.；There are 5 notifications provided by 5 of 6 reports by companies with hazard statement code(s).；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Flam. Liq. 3 (16.7%)；Skin Irrit. 2 (33.3%)；Skin Sens. 1 (33.3%)；Eye Irrit. 2 (33.3%)；Acute Tox. 4 (16.7%)；STOT SE 3 (16.7%)；Muta. 1B (16.7%)；Carc. 1B (16.7%)；Carc. 2 (16.7%)；Repr. 1B (33.3%)；Aquatic Chronic 2 (16.7%)

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Doxifluridine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Antimetabolites that are useful in cancer chemotherapy.

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.

Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and AIDS.

Kidney；Liver

Cytoplasm

Capecitabine Action Pathway；Capecitabine Metabolism Pathway